Welcome to our dedicated page for Doximity SEC filings (Ticker: DOCS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Doximity, Inc. (DOCS) SEC filings page provides access to the company’s official regulatory disclosures as a New York Stock Exchange–listed issuer. Doximity files annual, quarterly, and current reports that describe its financial condition, results of operations, governance matters, and material events affecting the business.
In its filings and related press releases, Doximity presents condensed consolidated balance sheets, statements of operations, and statements of cash flows, along with discussions of non-GAAP financial measures. The company explains how it calculates metrics such as non-GAAP gross profit, non-GAAP net income, adjusted EBITDA, and free cash flow, and provides reconciliations to GAAP results. These documents allow readers to see how Doximity evaluates its performance beyond standard accounting measures.
Current reports on Form 8-K for DOCS include items such as quarterly earnings announcements, changes in executive roles, annual meeting voting results, and legal developments. For example, Doximity has filed 8-Ks to furnish earnings press releases, to report the outcomes of its annual meeting of stockholders, to disclose changes in its general counsel and related roles, and to describe a securities litigation settlement agreement that remains subject to court approval and other customary conditions.
Through its proxy materials and related filings, Doximity also reports on corporate governance topics, including the election of directors, ratification of its independent registered public accounting firm, and advisory votes on executive compensation. Voting results, including the participation of Class A and Class B common stock, are detailed in these documents.
On this page, AI-powered tools can summarize lengthy DOCS filings, highlight key sections on revenue trends, profitability, cash flows, and risk disclosures, and surface notable items such as settlement agreements or executive transitions. Users can quickly review quarterly reports, annual reports, and Form 4 and other transaction-related filings, while relying on real-time updates from the SEC’s EDGAR system to follow new disclosures from Doximity, Inc.
Doximity (NYSE:DOCS) filed a Form 4 revealing that director Regina M. Benjamin exercised 10,000 stock options at $2.21, converted the resulting Class B shares into Class A, and immediately sold those 10,000 Class A shares at $60 on 06/25/2025. The trade was executed under a pre-arranged Rule 10b5-1 plan adopted 02/26/2025.
The gross proceeds total roughly $600,000, representing about 38% of Benjamin’s direct Class A position before the sale. After the transactions she still directly owns 16,618 Class A shares and holds 371,138 option shares.
Doximity (NYSE:DOCS) director Timothy S. Cabral filed Form 4 reporting a same-day option exercise and sale on 06/25/2025.
Cabral converted 10,000 Class B shares into Class A at a $2.21 strike, then sold the entire block at $60.00 per share under a Rule 10b5-1 plan adopted 02/13/2025, generating roughly $600,000 in gross proceeds. His direct Class A holdings fell from 16,360 to 6,360 shares, a 61% reduction. No additional acquisitions or new compensation arrangements were disclosed.
Form 144 Notice of Proposed Sale filed for Doximity (NYSE: DOCS) indicates an insider sale transaction. Timothy Cabral plans to sell 10,000 shares of common stock with an aggregate market value of $600,000, to be executed through Morgan Stanley Smith Barney LLC.
Key transaction details:
- Securities were acquired through stock option exercise on June 25, 2025
- Sale represents a small fraction of total outstanding shares (187,826,153)
- Planned execution date: June 25, 2025
- Previous sale by the same insider: 10,000 shares sold on May 23, 2025 for $505,796
This Form 144 filing represents a declaration of intent to sell securities and confirms the seller has no knowledge of undisclosed material adverse information regarding Doximity's operations.
The Form 144 filing submitted on behalf of Doximity, Inc. (DOCS) discloses a proposed sale of 10,000 common shares through broker Morgan Stanley Smith Barney LLC. The shares—acquired via a stock-option exercise on 06/25/2025—carry an aggregate market value of $600,000. With 187,826,153 shares outstanding, the transaction represents roughly 0.005 % of total shares, indicating an immaterial dilution impact. The seller reported no prior sales in the last three months and affirmed awareness of no undisclosed adverse information. The planned sale is scheduled for on or after 06/25/2025 on the NYSE under Rule 144, reflecting routine insider liquidity while complying with SEC disclosure requirements.